TP53 and rectal cancer: Sclafani et al. used the mutation status of five genes (KRAS, NRAS, BRAF, PIK3CA, and TP53) to analyze the clinical features and treatment results of rectal cancer and found that mutations in these five genes would increase the recurrence and prevalence of rectal cancer [10].